Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gefitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 16/20 | 0.80 |
| ▸ | KDR | P35968 | 3/20 | 0.79 |
| ▸ | BRAF | P15056 | 2/20 | 0.79 |
| ▸ | SRC | P12931 | 2/20 | 0.79 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.79 |
| ▸ | CIT | O14578 | 1/20 | 0.79 |
| ▸ | GAK | O14976 | 1/20 | 0.79 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.79 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.79 |
| ▸ | STK17B | O94768 | 1/20 | 0.79 |
| ▸ | STK10 | O94804 | 1/20 | 0.79 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.79 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.79 |
| ▸ | ABL1 | P00519 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gefitinib SCHEMBL28140379 | 0.99 | EGFR (0.79) | EGFRKDRBRAFSRCEPHB4 | |
| Gefitinib SCHEMBL28140377 | 0.99 | EGFR (0.78) | EGFRKDRBRAFSRCEPHB4 | |
| SCHEMBL29483201 | 0.90 | EGFR (1.00) | EGFRKDRBRAFSRCEPHB4 | |
| SCHEMBL828788 | 0.90 | EGFR (1.00) | EGFRKDRBRAFSRCEPHB4 | |
| Hydrochloric Acid SCHEMBL20534441 | 0.89 | EGFR (0.98) | EGFRKDRBRAFSRCEPHB4 | |
| Hydrochloric Acid SCHEMBL30133464 | 0.89 | EGFR (0.98) | EGFRKDRBRAFSRCEPHB4 | |
| Gefitinib SCHEMBL29351046 | 0.89 | EGFR (1.00) | EGFRKDRBRAFSRCEPHB4 | |
| SCHEMBL1734701 | 0.89 | EGFR (1.00) | EGFRKDRBRAFSRCEPHB4 | |
| Gefitinib SCHEMBL29351336 | 0.89 | EGFR (1.00) | EGFRKDRBRAFSRCEPHB4 | |
| Gefitinib SCHEMBL465143 | 0.89 | EGFR (1.00) | EGFRKDRBRAFSRCEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3170824-A1 | 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS | Amgen, Inc (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-2598168-A2 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2593107-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2584903-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012015741-A2 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-2288383-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009140549-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2009-11-19 | — | — | WO | disclosed |